cyrilzakka/clinical-trials huggingface dataset:
Comparison of Costoclavicular and Paracoracoid Approaches to Infraclavicular Brachial Plexus Blocks

Infraclavicular block has taken its place in the literature as a proven technique in the anesthetic management of upper extremity surgeries. Compared to general anesthesia; The prominent advantages of regional anesthesia are that it provides longer perioperative pain control, reduces the incidence of postoperative nausea and vomiting, reduces opioid consumption and reduces the cost of hospitalization. The widespread use of ultrasonography (USG) in the last two decades has facilitated the application of the method and allowed the investigation of different injection methods.

Regional blocks are planned according to the surgery to be performed. For anesthesia of arm, forearm and hand operations; brachial plexus can be blocked in the axillary, infraclavicular, supraclavicular or interscalene region. The infraclavicular technique, on the other hand, is roughly divided into three types: costoclavicular lateral, costoclavicular medial and paracoracoid (Lateral sagittal). The image obtained by placing the ultrasonography probe in the relevant anatomical region serves as a guide for the orientation of the peripheral block needle and performing the intervention by observing the vascular structures in the existing region provides a great advantage in terms of patient safety.

In this study, we aimed to examine 3 different infraclavicular block methods; lateral costoclavicular, medial costoclavicular and lateral sagittal (Paracoracoid) approach, in terms of ease of application and motor/sensory block efficiency. Our hypothesis is that the sensory block will begin in a shorter time with costoclavicular methods compared to the lateral sagittal method. We are also planning to compare performance difficulties (needle maneuver numbers, subjective block exertion, block performance time etc.) for each type of intervention.


Eligibility Criteria:
Inclusion Criteria:

* Patients scheduled for elective upper extremity surgeries (Arm, upper-arm and hand)

Exclusion Criteria:

* Patients with bleeding diathesis Presence of infection on the intervention site Patients requiring continous anticoagulation therapy due to the existing comorbidities Patients with history of local anesthetic allergy Pregnant patients
Medication Adherence and Non-adherence in Adults With Rare Disease

The purpose of this study is to use the Medication Adherence Reasons Scale (MAR-Scale) to determine the extent of non-adherence to specific medications indicated to treat cystic fibrosis, hemophilia (A or B), idiopathic pulmonary fibrosis, myasthenia gravis, and sickle cell disease, and to identify the top patient-reported reasons for non-adherence. Internal reliability of the MAR-Scale will also be assessed in each condition.


Eligibility Criteria:
Inclusion Criteria:

* Have a confirmed (self-reported) diagnosis by a doctor or other licensed healthcare professional of one of the following conditions:
* Cystic fibrosis
* Hemophilia (A or B)
* Idiopathic pulmonary fibrosis
* Myasthenia gravis
* Sickle cell disease
* Have access to the internet
* Are aged 18 years or above
* Are comfortable reading and answering questions in English
* Have an active prescription for at least one medication indicated to treat the relevant condition (self-reported)
* NB: Individuals will be eligible even if the prescription has not been dispensed (filled) yet, and also if they have the medication(s), but are not actually taking it/them Are able and willing to provide consent electronically through the my.raremark.com platform

Exclusion Criteria:

* There are no exclusion criteria. Any member of a Raremark community will be able to take part in this study if they meet the inclusion criteria and can provide their informed consent.
The Influence of the Diaphragm Muscle and Pain Perception on Lower Limb Neuromuscular Control in Sports Practice.

Core stability is maintained mainly by muscle function of abdominal and lumbar region, including the diaphragm muscle. It is known that exists a connection between trunk's muscle activity and the movement of lower limb and lower limb and low back injuries are related to core alterations. Thus, a randomized clinical trial is planned to analyze the effectiveness of an exercises and manual therapy of the diaphragm and ribs program designed, aiming to analyze the correlation between rib cage mobility and lower limb neuromuscular control in young healthy subjects.

The aim of the study consists on analysing the correlation between rib cabe mobility and neuromuscular control parameters of lower limb, as well as pain perception in young healthy adults sports players. A clinical practice protocol consisting on breathing exercises and manual therapy of the muscle diaphragm and the ribs will be applied twice a week during eight weeks. As a result, could be an increasement of the neuromuscular control parameters, described with the outcome measures of rib cage mobility, lower limb power and stability, and pain perception. If the results stablish correlation between the rib cage mobility and neuromuscular control parameters of lower limb, could be helpful in healthcare and sports science field in order to take in account the diaphragm biomechanics when treating lower limb injuries and facing its prevention.

Eligibility Criteria:
Inclusion Criteria:

* Physical Activity Practice: at least 150-300min of moderate activity or 75-100min of intense aerobic activity, twice a week.
* Physical activity or sports practice involve mostly lower limb muscles activation.
* Core Stability exercises least twice a week. Includes at least 3 of the 6 exercises listed: bridge exercises, standard plank, lateral plank, superman exercise, mountain climber and plank variations.

Exclusion Criteria:

* Musculoskeletal injury currently or in the past 6 months.
* Abdominal or thoracic surgery.
* Nervous System disease.
* Hiatal Hernia or visceral disease.
* Pelvic floor alterations or disease.
* Breathing restrictions: disease or infection, asthma, anxiety or other non controlled alterations.
* Treatment of the diaphragm muscle the past 6 months.
Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions

This is a 12-week, multicenter, open-label extension study to evaluate the safety and efficacy of TNX-102 SL tablet taken daily at bedtime in patients with Military-Related PTSD or related condition. Patients recruited into this trial are those who have successfully completed the double-blind study, TNX-CY-P201 (AtEase Study) \[NCT02277704\]. Patients will not be made aware of the therapy they received during the double-blind study.

The study will consist of 4 clinic visits, including Screening/Baseline Visit 1 (Day 0, which is anticipated to be the same date as the final visit in the lead-in P201 study) and visits after 2, 6 and 12 weeks of treatment. The previous requirements in the lead-in study for refraining from the use of certain concomitant medications and trauma-focused psychotherapies will be relaxed. Patients may continue to take rescue therapy for sleep, as appropriate, or they may utilize other medications as needed to help them sleep, per the judgment of the investigator.

Eligible patients who provide written informed consent will take one TNX-102 SL tablet daily at bedtime sublingually (under the tongue) for 12 weeks. All patients will be assigned to receive tthe same dosage of TNX-102 SL, regardless of their treatment assignment in the lead-in study. No patients, investigators, or study staff will know the assigned study treatment from the lead-in study, P201, at the time of entry into the extension study. Patient data collected at the Week 12 visit (Visit 9) in the lead-in P201 study will be used as one of the baseline values for this study.

Eligibility Criteria:
Inclusion Criteria:

* Completed the lead-in study and is judged as reasonably compliant, with at least 60% compliance
* Signed informed consent
* Met all prior inclusion and exclusion requirements for lead-in study
* No new or worsening medical conditions since starting the lead-in study that could pose a safety risk or interfere with participation in the study
* Willing to refrain from use of specific medication (ask PI)
* Female patients of childbearing potential continue to practice medically acceptable methods of birth control

Exclusion Criteria:

* None
Effect of SMS Reminder and Free Eye Drops on Follow-up Adherence After Trabeculectomy Surgery in Rural China

The purpose of the study is to use a randomized controlled design to determine the impact of a SMS messaging associated with free eye drops intervention on the following outcomes among patients after trabeculectomy surgery in rural China.

SMS message reminder is a system which can sent re-visit information to remind the patient about the revisit time and address. The investigators can use the SMS system to find out if it is a useful to reduce the not-attended rate of the revisit appointment among the rural patients.

Eligibility Criteria:
Inclusion Criteria:

* All the patients after trabeculectomy surgery in 4 cooperated rural hospitals

Exclusion Criteria:

* Both the patient and his/her caretakers don't have cellphone or the one who has cellphone but don't know how to use the SMS function.
Anderson-Fabry Disease in Chronic Kidney Disease Patients Not on Renal Replacement Therapy

Anderson-Fabry disease is a rare X-linked lysosomal storage disorder due to the deficiency of alfa-galactosidase A (AGAL). The subsequent accumulation of glycosphingolipids may lead to to cardiac, renal, and central nervous system impairment as well as premature death. Recently published studies suggest that the true incidence of the disease may be underestimated in certain risk groups, e.g. in patients with chronic kidney disease (CKD).

Therefore, the investigators initiated a multicenter case-finding study in Austria by screening patients with chronic kidney disease not yet on renal replacement therapy. Molecular isoforms of globotriaosylceramide (Gb3), characterized by different chain lengths of their N-acyl residues, will be determined in a urine sample. Characteristic parameters, including the ratio of C24/C18 isoforms will be used for identifying patients liable to have the disease. A positive result will be confirmed by biochemical and genetic testing.

A sample size of 5.000 chronic kidney disease patients is envisaged allowing for detection of 1 to 25 patients with Anderson-Fabry disease.


Eligibility Criteria:
Inclusion Criteria:

* Chronic kidney disease KDOQI stage 1-5
* Informed consent

Exclusion Criteria:

* Patients already on renal replacement therapy
* Not willing to participate
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is more effective than best supportive care alone, for the treatment of patients with non-small cell lung cancer, whose disease has recurred after previous chemotherapy and an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI). ZD6474 is a new anti-cancer drug in development that works in a different way to standard chemotherapy drugs. It targets the growth of new blood vessels to a tumour and thereby might slow the rate at which the tumour may grow. Early studies indicate that ZD6474 has a positive effect on the time that a tumour may take to progress to a further stage. Approximately 930 patients will take part in this study. It will be conducted in hospitals and clinics in North and South America, Europe and Asia.


Eligibility Criteria:
Inclusion Criteria:

* Patients with Non-small cell lung cancer for which the standard cancer treatments of surgery, chemotherapy, radiation or other anticancer drugs are no longer appropriate treatments for you.

Exclusion Criteria:

* Patients who have had standard cancer treatments of surgery, chemotherapy or other systemic anti-cancer therapy within 4 weeks before start of study therapy.
* Three or more prior chemotherapy regimens.
* Significant cardiovascular events.
Parity and Serum Lipids in White and Hispanic Women

To analyze the relationships between parity (childbirth) or gravidity (pregnancy) and measures of lipids in groups of women from the Hispanic Health and Nutrition Examination Survey (Hispanic HANES) and the Framingham Heart Study.

BACKGROUND:

The relationships between parity or gravidity and measures of lipids in groups of women from the Hispanic Health and Nutrition Examination Survey (Hispanic HANES) and the Framingham Heart Study offered insights into the health of an important minority group in the United States and provided clues regarding hormonal mechanisms in lipoprotein metabolism.

DESIGN NARRATIVE:

In the Framingham cohort, the relationships among gravidity, LDL-cholesterol, HDL-cholesterol and total cholesterol were prospectively studied. Each of these serum lipids was tested as a potential mediator of associations between gravidity and various cardiovascular endpoints. In the Hispanic HANES, the associations among parity, gravidity, and lipid levels were examined in cross-sectional data on women of a different ethnic background in whom birth rates tended to be high. Secondary analysis of these two datasets was conducted, carefully considering aspects of the study designs. Bivariate analyses generated mean lipid levels within parity or gravidity groups. HDL, LDL, and total cholesterol were then stratified both by parity and other variables (such as age and smoking status) so that interactions could be considered. Multivariate analyses were used to analyze the effect of parity on lipids and cardiovascular disease events while controlling for a variety of potentially confounding factors (such as body mass index, subscapular/triceps, skinfold ratio, education, income, cigarette smoking, alcohol consumption, oral contraceptive use, estrogen replacement therapy, menopausal status and type of menopause). Interactions were also considered in multivariate models.

Eligibility Criteria:
No eligibility criteria
Utilizing Novel Dipole Density Capabilities to Objectively Visualize the Etiology of Rhythms in Atrial Fibrillation

A prospective, single-arm, multi-center, multi-national, non-randomized, post-market study designed to provide clinical data regarding the use of the AcQMap™ System in the ablation of persistent atrial fibrillation. (CL-AF-002 - EU)

A prospective, single-arm, multi-center, multi-national non-randomized study designed to provide clinical data regarding the use of the AcQMap™ System in the ablation of persistent atrial fibrillation. (CL-AF-001 - Canadian)

A prospective, single-arm, multi-center, multi-national, non-randomized, post-market study designed to provide clinical data regarding the use of the AcQMap™ System in the ablation of persistent atrial fibrillation. (CL-AF-002 - EU)

A prospective, single-arm, multi-center, multi-national non-randomized study designed to provide clinical data regarding the use of the AcQMap™ System in the ablation of persistent atrial fibrillation. (CL-AF-001 - Canadian)

The research study was conducted in the EU and Canada. The protocol and the corresponding NCT number is as follows:

NCT02462980 (Protocol CL-AF-001, Site Ontario, Canada Dr. Verma = PI)

The above record was combined into one as both protocols are essentially identical (one is post market \[EU\] and the other pre-market \[Canada\] and one study report will be written that encompasses the data/results for both protocols.

Eligibility Criteria:
Inclusion Criteria:

* Scheduled for an ablation of persistent atrial fibrillation

Exclusion Criteria:

* Any duration of continuous AF lasting longer than 12 months
* Previous AF ablation
* Significant structural heart disease
* Previous cerebral infarct
* Major bleeding disorders
* Pregnant or lactating
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults with Gorlin Syndrome

The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use.

People who take part will apply either Patidegib Gel 2% or a Vehicle Gel (with no active drug substance) to their face twice a day for a year (12 months). The number of new BCCs on the face will be compared between those who used Patidegib Gel 2% or Vehicle Gel after 12 months.

This is a global, multicenter, randomized, double-blind, stratified, vehicle-controlled study of the efficacy and safety of Patidegib Gel 2%, applied topically twice daily to the face of adult subjects with Gorlin syndrome.

Subjects will be randomized (1:1) to receive either Patidegib Gel 2% or Vehicle Gel for 12 months.

The assignment of subjects to the 2 groups will be stratified by sex assigned at birth, age (≥60 or \<60 years), and number of BCC lesions at the treatment area (face) (10-15, 16-30 or \>30) at Baseline.

All suspicious lesions will be imaged and tracked consistently throughout the study so that new BCCs that arise can be readily identified. New BCCs will be confirmed by dermoscopic analysis through the study. The BCC images will be reviewed and assessed by a Central Photo Review Board (CPRB).

Eligibility Criteria:
Key Inclusion Criteria:

1. The subject must be at least 18 years old at the Screening Visit.
2. The subject must be confirmed to have a PTCH1 mutation.
3. The subject must have at least 10 BCCs on the face at Randomization (Baseline/Day 1).
4. The subject must be willing to abstain from application of any non-study topical medication (prescription or over the counter) to their facial skin for the duration of the trial, except as prescribed by the investigator.

Key Exclusion Criteria:

1. The subject has used topical treatment to the face or systemic therapies that might interfere with the evaluation of the study Investigational Product (IP).
2. The subject is known to have hypersensitivity to any of the ingredients in the IP formulation.
3. The subject has uncontrolled systemic disease.
4. The subject has been treated for invasive cancer within the past 5 years excluding chronic lymphocytic leukemia Stage 0, non-melanoma skin cancer, successfully treated melanoma in situ and Stage I melanoma, Stage I cervical cancer, or ductal carcinoma in situ of the breast.
5. Inefficacy of previous Hedgehog inhibitor therapy.
A Suggested Rehabilitation Protocol for the Treatment of C-shape Scoliosis

This study aims to compare the effectiveness of mechanical traction and 3D apical vertebral mobilization and active exercises on Cobb's angle, spinal ROM, and function in patients with C-shaped scoliosis.

Scoliosis is a skeletal issue causing asymmetries, leading to functional disruptions. Common symptoms include uneven eye tilt, drop asloped shoulder, and muscle imbalances. These changes can affect the patient's physical appearance and psychological state. Current treatments have shown suboptimal results due to the lack of accepted scientific theories for idiopathic scoliosis. Therefore, a new therapeutic approach is needed to provide novel insights and improve treatment outcomes. This underscores the need for a more comprehensive approach to scoliosis treatment.

Eligibility Criteria:
Inclusion Criteria:

1. Adult individuals aged 18 to 30 years (after complete ossification and before the start of the ageing process and joint changes) as mentioned in studies.
2. Thoracolumbar scoliosis with Cobb angle between 10 to 30 degrees because a curve below 10 degrees has no effect and above 30 is indicated for surgery.

Exclusion Criteria:

1. History of orthopaedic surgeries.
2. History of road traffic accidents (RTA).
3. Myopathy.
4. True leg length discrepancy.
5. Neuropathy.
6. Mental disorders.
7. Bone tumor.
8. Heart disease or circulatory problems.
9. Early osteoporosis.
Brain Abnormalities in Late-Onset Major Depression

The objective of this project is to examine the state of the brain in people over 50 years old suffering from late-onset depression by means of an extensive clinical assessment programme, including magnetic resonance imaging (MRI), neuropsychological testing, neurological examination, eye examination as well as blood and saliva samples. The results are to be compared with results from a control group matched for gender and age.

Major depression is a frequent and serious disorder with different prognoses and complications with respect to lack of treatment response, recurrence and suicide.

MRI of the brain can provide information about changes in the brain tissue with depression, e.g. lesions of nerve connections, small thrombi or changes in the blood flow. These changes appear primarily after the age of 50 and are seen in cases of diabetes and high blood pressure. Furthermore, the connection between disruptions in the body's stress response system and depression will be explored, which is very important since studies indicate that stress and depression can affect certain brain parts permanently. This will give us a better understanding of the connection between brain changes, neuropsychology and depression prognosis, which is decisive for accurate diagnostics, effective treatment and targeted prevention of the disease in the long run.

The project is part of a larger clinical assessment programme in the Neuropsychiatric Unit under the Centre for Basic Psychiatric Research, Aarhus Psychiatric Hospital, Denmark, which gives us unique possibilities of combining research and daily clinical work. The hope is in the future to be able to offer patients in the risk group better assessment and treatment to prevent complications and recurrence.

Eligibility Criteria:
Inclusion Criteria:

* first time major depression
* age over 50 years
* Caucasian
* admitted at a psychiatric hospital or treated at a local psychiatric clinic in Aarhus Amt

Exclusion Criteria:

* major brain damage (e.g. stroke, epilepsy, trauma)
* major alcohol or drug abuse
Prevention of Injuries in Young Athletics (Track and Field) Athletes

The long-term purpose of an on-going participatory action research program "The KLUB-study" in Sweden, that involves scientists and representatives from all levels of athletics, is to develop a sustainable framework for safe athletics (track and field) training for child athletes born 2002-2006. The first part of the research program, a 1-year longitudinal study analysing training and injury data, was completed in November 2017. The present study sets out to evaluate a website that aims to support coaches and caregivers in their role as adult key stakeholders to foster young athletes to become adult athletes who possess the tools to maintain a healthy sporting lifestyle.

The intervention will be implemented in youth athletics and evaluated in a randomised controlled trial (RCT). It will follow the consensus guidelines for studies in athletics and be reported according to the CONSORT checklist. The participating clubs will be randomly allocated into active and control group. The active group will be provided the intervention program, i.e. access to a website, aimed to support coaches, caregivers´ and athletes' and improve knowledge and health literacy to make more informed choices that promote health. The control group will continue to train according to their routines and will get access to the website after 4 months.

The participants will be assessed at three times, at the beginning of the study (T1), after four months (T2), at ten months (T3) and additional prospective data on training and injury will be collected during the first four months (T1b).

Eligibility Criteria:
Inclusion Criteria:

* belonging to a sports club and participate in organized training, athletics (track and field)
* born 2002 - 2006

Exclusion Criteria:

* not, on a regular basis, participating in athletics (track and field) training